111 – 120 of 157
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2001
-
Mark
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer
(
- Contribution to journal › Article
-
Mark
Image cytometric Auer class-I identifies a real low risk group among lymph node negative premenopausal breast cancer patients
(
- Contribution to journal › Published meeting abstract
-
Mark
Histological grade, its three components and flow cytometric S-phase as prognostic markers in premenopausal women with node negative breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase) : association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients
(
- Contribution to journal › Article
-
Mark
Timing of quality of life (QoL) assessments as a source of error in oncological trials
(
- Contribution to journal › Article
- 2000
-
Mark
Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
(
- Contribution to journal › Article
-
Mark
Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy?
(
- Contribution to journal › Article
-
Mark
A randomised study of sector resection with and without radiotherapy for women with node-negative stage I and II breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : a randomised trial
(
- Contribution to journal › Article
-
Mark
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer
(
- Contribution to journal › Article